Business
Regen BioPharma, Inc.'s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6
Regen BioPharma, Inc.'s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6.
About this update from Regen Biopharma, Inc.
[{"type":"text","content":"\n\n\n\nRegen BioPharma, Inc.'s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6\n\n\n\n\n\nRegen BioPharma, Inc.'s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6\nThe company is rapidly expanding the number of activating compounds in its portfolio\nPR Newswire\nSAN DIEGO, January 17, 2018\n\n\n\nSAN DIEGO, January 17, 2018 /PRNewswire/ --\n\nRegen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. These studies were conducted at ChemDiv Inc., the Company's contract research organization.\n\n\"We recently identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. In order to ensure that we capture as much intellectual property as possible, we screened a new 48,000 compound library containing diverse compounds,\" says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. \"In doing so, we identified 25 new compounds that activate NR2F6. Remarkably, each newly-identified compound contained the key structure that we previously identified. This tells us that it is likely the key structural element we identified is an absolute requirement for activating NR2F6. We anticipate utilizing our three-dimensional x-ray crystallography program to attempt to provide a clear molecular picture of this recently identified element.\"\n\n\"This additional information supports our prior work in this area and gives us confidence we are indeed on the right path,\" says David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc. \"I am delighted that the agonist program is moving ahead in such a positive manner.\"\n\nThe NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.\n\nAbout Regen BioPharma Inc.:  \n\nRegen Bio...